The news directly pertains to Tandem Diabetes Care as Baird analyst Jeff Johnson has maintained a Neutral rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's market performance. However, as the rating remains Neutral, the immediate impact on the stock price might be limited.